SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 128 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 4.34 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $10,582 | -48.0% | 29,535 | -2.8% | 0.00% | – |
Q1 2024 | $20,359 | -91.8% | 30,378 | +90.4% | 0.00% | – |
Q4 2020 | $249,000 | +87.2% | 15,957 | +38.1% | 0.00% | – |
Q4 2018 | $133,000 | -84.6% | 11,551 | -77.3% | 0.00% | -100.0% |
Q3 2018 | $861,000 | +8.7% | 50,782 | -8.9% | 0.00% | 0.0% |
Q2 2018 | $792,000 | -36.6% | 55,740 | -15.2% | 0.00% | 0.0% |
Q1 2018 | $1,249,000 | +35.0% | 65,736 | +16.6% | 0.00% | 0.0% |
Q4 2017 | $925,000 | +16.5% | 56,372 | +6.6% | 0.00% | 0.0% |
Q3 2017 | $794,000 | +32.1% | 52,901 | -5.1% | 0.00% | -50.0% |
Q3 2014 | $601,000 | -29.4% | 55,742 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $851,000 | -15.6% | 55,742 | 0.0% | 0.00% | -33.3% |
Q1 2014 | $1,008,000 | +31.8% | 55,742 | +1.3% | 0.00% | +50.0% |
Q4 2013 | $765,000 | +10.1% | 55,042 | -17.0% | 0.00% | 0.0% |
Q3 2013 | $695,000 | +34.2% | 66,300 | 0.0% | 0.00% | 0.0% |
Q2 2013 | $518,000 | +402.9% | 66,300 | +287.7% | 0.00% | – |
Q4 2012 | $103,000 | – | 17,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |